Markets
ABT

Roche Presents Positive Data on Respiratory Drug Esbriet

An image of a stock chart
Credit: Shutterstock photo

RocheRHHBY announced positive data on idiopathic pulmonary fibrosis (IPF) drug, Esbriet from two phase III studies - ASCEND and CAPACITY. Data was presented at the European Respiratory Society congress in Amsterdam.

The results showed a 38% reduction in risk of death in patients suffering from IPF, who continued treatment with Esbriet for two years as compared with placebo.

The results reinforced the efficacy of Esbriet in reducing the risk of death in the long run in IPF patients. At the end of one year, the study had shown a 48%reduction in the risk of mortality after treatment with Esbriet.

Moreover, an ad-hoc analysis of the pooled data from ASCEND and CAPACITY showed that patients, who were hospitalized within the first six months of treatment, showed reduced risk of disease progression or death by more than two-thirds at one year on continued treatment with Esbriet.

We remind investors that Roche had added Esbriet to its respiratory portfolio following the acquisition of InterMune in Sep 2014. Esbriet was approved by the FDA in 2014 for the treatment of IPF. The drug was approved in Europe in 2011.

Roche's respiratory portfolio includes Xolair for severe asthma, Pulmozyme for cystic fibrosis, and Esbriet. The company also has a pipeline candidate - lebrikizumab - in phase III for severe uncontrolled asthma and targets IL-13. We are encouraged by Roche's efforts to broaden its drug portfolio beyond oncology.

Roche currently carries a Zacks Rank #3 (Hold). Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . All three carry a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report

NOVO-NORDISK AS (NVO): Free Stock Analysis Report

ABBOTT LABS (ABT): Free Stock Analysis Report

ABBVIE INC (ABBV): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ABT RHHBY NVO ABBV

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More